TrialDrug design, development and therapy2025

The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Administration of a Novel Anti-NGF Monoclonal Antibody (AK115) in Healthy Participants: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Clinical Trial.

Juan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.